论文部分内容阅读
目的 探讨长程低剂量罗盖全维持治疗慢性肾衰竭(CRF)早期继发性甲旁亢(SHPT)的必要性、疗效和安全性。方法 选择2000-01～2004-02经罗盖全治疗达到观察终点、血清iPTH为正常值2.5倍和3倍的早期SHPT患者共218例随机分为治疗组和对照组,治疗组分别给予隔日和每日0.25μg罗盖全进行为期2年的维持治疗,对照组不使用罗盖全。结果 治疗组中83.33％～94.12％血清iPTH质量浓度维持在正常值2～3倍的理想范围,明显高于对照组的5.58％～45.45％,P<0.01。结论 对经罗盖全治疗血清iPTH质量浓度降至正常值2.5倍和3倍的SHPT患者分别予隔日和每日口服0.25μg罗盖全维持治疗2年是必要、有效和安全的。
Objective To investigate the necessity, efficacy and safety of long-range, low-dose caprolactam for the treatment of early secondary hyperparathyroidism (CRP) of chronic renal failure (SHPT). Methods A total of 218 patients with early stage SHPT whose serum iPTH was 2.5-fold and 3-fold normal after Luo Gai-Quan treatment reached the end of treatment from 2000-01 to 2004-02 were randomly divided into treatment group and control group, 0.25μg cap daily cover all for a period of 2 years of maintenance treatment, the control group does not use Luo cover all. Results The concentration of iPTH in 83.33% -94.12% of the treatment group was maintained in the ideal range of 2 ~ 3 times of the normal value, which was significantly higher than that of the control group (5.58% -45.45%, P <0.01). Conclusion It is necessary, effective and safe to treat patients with SHPT whose serum concentration of iPTH dropped to 2.5 times and 3 times of the normal value after taking Luo Gaiquan serum respectively.